Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01K-067/027
A61L-027/36
C12N-009/10
C12N-015/85
A61K-035/12
출원번호
US-0449969
(2014-08-01)
등록번호
US-10130737
(2018-11-20)
발명자
/ 주소
Ayares, David
Rohricht, Paul
출원인 / 주소
Revivicor, Inc.
대리인 / 주소
King & Spalding
인용정보
피인용 횟수 :
0인용 특허 :
22
초록▼
The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or a
The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
대표청구항▼
1. A tissue product comprising a tissue stripped of viable cells wherein the tissue is derived from a tissue of a porcine animal in which both alleles of the alpha-1,3-galactosyltransferase gene are inactive, wherein at least one allele is rendered inactive through at least one point mutation, and t
1. A tissue product comprising a tissue stripped of viable cells wherein the tissue is derived from a tissue of a porcine animal in which both alleles of the alpha-1,3-galactosyltransferase gene are inactive, wherein at least one allele is rendered inactive through at least one point mutation, and the animal lacks expression of alpha-1,3-galactosyltransferase. 2. The tissue product of claim 1, wherein the tissue is a hard tissue. 3. The tissue product of claim 1, wherein the tissue is a soft tissue. 4. The tissue product of claim 2, wherein the hard tissue is bone or a fragment or derivative thereof. 5. The tissue product of claim 3, wherein the soft tissue is selected from the group consisting of skin, dermal, submucosal, ligament, tendon and cartilage or a fragment or derivative thereof. 6. The tissue product of claim 1, wherein the tissue is a combination of hard and soft tissue. 7. The tissue product of claim 6, wherein the tissue is a bone-tendon-bone graft. 8. The tissue product of claim 1, wherein at least one allele of the alpha-1,3-GT gene is rendered inactive by a genetic targeting event. 9. The tissue product of claim 8, wherein the genetic targeting event is homologous recombination. 10. The tissue product of claim 8 or 9, wherein the genetic targeting event uses a targeting construct directed to exon 9 of the alpha-1,3-GT gene. 11. The tissue product of claim 8, wherein both alleles of the alpha-1,3-GT gene are rendered inactive through at least one point mutation. 12. The tissue product of claim 8, wherein the at least one point mutation of the alpha-1,3-GT gene is a substitution, deletion or insertion mutation or a combination thereof. 13. The tissue product of claim 8, wherein at least one point mutation of the alpha-1,3-GT gene is a T-to-G point mutation at the second base of exon 9. 14. The tissue product of claim 13, wherein the T-to-G point mutation at the second base of exon 9 in both alleles of the alpha-1,3-GT gene. 15. The tissue product of claim 8, wherein an allele of the alpha-1,3-GT gene is rendered inactive through at least two point mutations. 16. The tissue product of claim 8, wherein the tissue stripped of viable cells is produced by enzymatic treatment. 17. The tissue product of claim 8, wherein the tissue is bone. 18. The tissue product of claim 8, wherein the tissue stripped of viable cells is produced by chemical treatment. 19. The tissue product of claim 8, wherein the tissue is selected from the group consisting of tendon, joint, bone and heart valve. 20. The tissue product of claim 9 or 11, wherein the tissue can be further processed via crosslinking treatments. 21. The tissue product of claim 17 or 19, wherein the tissue can be further processed via additional chemical treatments.
Yiannis Ioannou ; Robert J. Desnick ; Mauro S. Sandrin AU; Ian F. C. McKenzie AU, Cells expressing an .alpha.gala nucleic acid and methods of xenotransplantation.
Lebkowski Jane S. (Portola Valley CA) McNally Maureen A. (Palo Alto CA) Okarma Thomas B. (Palo Alto CA), Method for producing recombinant adeno-associated virus vectors.
Wilkins Tracy D. (Blacksburg VA) Krivan Howard C. (Blacksburg VA), Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors.
d'Apice Anthony J. F.,AUX ; Pearse Martin J.,AUX ; Robins Allan J.,AUX ; Crawford Robert J.,AUX ; Rathjen Peter D.,AUX, Mice homozygous for an inactivated .alpha. 1,3-galactosyl transferase gene.
D'Apice, Anthony J. F.; Pearse, Martin J.; Robins, Allan J.; Crawford, Robert J., Pigs and pig cells having an inactivated α 1,3-galactosyl transferase gene.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.